{"id":8073,"date":"2026-10-27T07:33:08","date_gmt":"2026-10-27T13:33:08","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=8073"},"modified":"2026-10-27T16:30:30","modified_gmt":"2026-10-27T22:30:30","slug":"igan-therapy-its-getting-crowded-out-there","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2026\/10\/27\/8073\/igan-therapy-its-getting-crowded-out-there\/","title":{"rendered":"IgAN Therapy \u2013 It\u2019s Getting Crowded Out There"},"content":{"rendered":"\n<figure class=\"wp-block-image alignwide size-large\"><a href=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/IGAN-DRUGS-e1793087424970.jpg?ssl=1\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" width=\"530\" height=\"149\" src=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/IGAN-DRUGS.jpg?resize=530%2C149&#038;ssl=1\" alt=\"\" class=\"wp-image-8081\"\/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Earlier this year, the NEJM published interim data on atacicept and sibeprenlimab in IgAN, both well-designed Phase 3 pivotal registration trials of promising drugs <a href=\"#_ftn1\" id=\"_ftnref1\">[1]<\/a>,<a href=\"#_ftn2\" id=\"_ftnref2\">[2]<\/a>. Sponsors were clearly anxious to show the world how well their drug is working, but why publish interim results?&nbsp; After all, IA data are usually not the last word on efficacy and can be misleading.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Well, the situation is slightly different for IgAN.&nbsp; there is really no doubt anymore that APRIL or BAFF\/APRIL inhibitors have efficacy in this disease.&nbsp; All compounds from this class have shown in aggregate that significant IgA lowering is achievable, with concomitant reduction in proteinuria.&nbsp; There is also considerable evidence of benefit regarding the underlying disease.&nbsp; Even if these drugs do not stop the gradual loss of kidney function, they can change the downhill trajectory considerably.&nbsp; Nobody will expect a reversal of damage already done.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Now the definitive data are in. Final results of large Phase 3 BAFF\/APRIL inhibitor studies were published in the NEJM for sibeprenlimab (APRIL inhibitor) and atacicept (BAFF\/APRIL inhibitor) both showing stabilization of eGFR,&nbsp; the all-important FDA approval criterium.<a href=\"#_ftn3\" id=\"_ftnref3\">[3]<\/a>,<a href=\"#_ftn4\" id=\"_ftnref4\">[4]<\/a>&nbsp; In the same issue interim results for povetacicept (BAFF\/APRIL inhibitor) and ravulizumab (C5a complement inhibitor) are presented as well; both showing impressive reductions in urinary albumin loss (see below).<a href=\"#_ftn5\" id=\"_ftnref5\">[5]<\/a>,<a href=\"#_ftn6\" id=\"_ftnref6\">[6]<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">All these studies were conducted with guidance of eminent nephrologists.&nbsp; We are treated to a barrage (we are tempted to call it a Barrattage!) of surprisingly similar outcomes:<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/image-2.png?ssl=1\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" width=\"530\" height=\"136\" src=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/image-2.png?resize=530%2C136&#038;ssl=1\" alt=\"\" class=\"wp-image-8077\" srcset=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/image-2.png?resize=1024%2C262&amp;ssl=1 1024w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/image-2.png?resize=767%2C196&amp;ssl=1 767w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/image-2.png?resize=300%2C77&amp;ssl=1 300w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/image-2.png?w=1382&amp;ssl=1 1382w\" sizes=\"auto, (max-width: 530px) 100vw, 530px\" \/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The enthusiasm is almost palpable; a new era is dawning for IgAN patients who only had RAAS and SGLT2 therapy for disease control until recently.&nbsp; The IgAN market is new territory and underserved; competition will be fierce.&nbsp; This is great news for patients and caregivers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With great efficacy and safety results, we will soon leave the clinical arena behind, entering commercial territory.&nbsp; What differentiation is there, if any?<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In line with prior data, ravulizumab was very well tolerated over the first 34 wks; it seems that the infection risk (esp. meningococcal) can be managed with prior vaccinations.&nbsp; IV dosing though every 2 months will probably not become the preferred option for CKD patients. Weight-based dosing, however, should not be a problem.&nbsp; The proposed dose regimen is sufficient to achieve C5 blockade through the entire 2-month period, with excellent efficacy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It appears that many different complement inhibitors can claim efficacy in IgAN.&nbsp; This includes<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>iptacopan, an oral factor B inhibitor with not so stellar results in IgAN (see PI)<\/li>\n\n\n\n<li>cemdisiran, an RNAi drug in Phase 3, administered SC q4wk targeting C5, with good results on proteinuria in a small Phase 2 trial<a href=\"#_ftn7\" id=\"_ftnref7\">[7]<\/a><\/li>\n\n\n\n<li>C3 inhibitors<\/li>\n\n\n\n<li>The MASP-2 inhibitor narsoplimab was discontinued, because efficacy over placebo could not be established.<a href=\"#_ftn8\" id=\"_ftnref8\">[8]<\/a>&nbsp;<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Is there a need for BAFF inhibition when APRIL blocking delivers the same efficacy?&nbsp; Belimumab, a pure BAFF inhibitor, has a positive effect on proteinuria, albeit to a lesser degree than seen with BAFF\/APRIL or pure APRIL inhibitors.<a href=\"#_ftn9\" id=\"_ftnref9\">[9]<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sibeprenlimab did just as well as the dual antagonists to the point of stopping disease progression.&nbsp;Quite impressive, I\u2019d say.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?ssl=1\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" width=\"530\" height=\"258\" src=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?resize=530%2C258&#038;ssl=1\" alt=\"\" class=\"wp-image-8078\" srcset=\"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?w=923&amp;ssl=1 923w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?resize=767%2C374&amp;ssl=1 767w, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/Rizk.jpg?resize=300%2C146&amp;ssl=1 300w\" sizes=\"auto, (max-width: 530px) 100vw, 530px\" \/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Figure 1: From: Rizk &#8211; NEJM 2026<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lacking other differentiating features, dosing convenience and price will become major drivers of market share: povetacicept and sibeprenlimab are q4wk SC drugs, atacicept is administered qwk SC.&nbsp; But these are not the only determinants of commercial success; the marketing muscle of Big Pharma needs to be factored in as well.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">IgA nephropathy was a disease without therapy 20 years ago.<a href=\"#_ftn10\" id=\"_ftnref10\">[10]<\/a>&nbsp; It was considered a rather indolent disease with slow progression towards ESRD.&nbsp; Textbooks, however, mention that some cases progress more rapidly, that abnormal galactosidation (or the lack thereof) referred to as Gd-IgA1 is found uniformly, and that IgA deposition on the glomerular membrane sets in motion a series of events (simplistically referred to as the 4-Hit Hypothesis) that seem to trigger glomerular damage resulting in proteinuria .&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It is now clear that APRIL inhibitors (on top of optimized ACE\/ARB\/SGLT2 therapy) can buy time. In the next few years long-term f\/u data will be generated.&nbsp; Then we will learn how much dialysis can be postponed or avoided altogether.&nbsp; On this, the jury is still out.&nbsp; But the advent of so many new therapeutics will drive awareness of the disease at rather early stages, with treatment being offered for some 30-40 yrs to come as most patients are young \u2013 middle age.&nbsp; It will be the next big gold mine for Pharmas unless CMMS, NICE or other gatekeepers step up their cost-control efforts.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In this context, you may be curious to learn more about telitacicept, a drug already approved for IgAN in China (and various other indications).\u00a0 Results of telitacicept studies in IgAN have been published and show comparable efficacy to other \u2018tacicepts\u2019.<a href=\"#_ftn14\">[14]<\/a>\u00a0\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">An internet search informs us that NRDL reimbursement for Telitacicept, a SC weekly injection, was <strong>RMB 2,586<\/strong> (approximately <strong>USD 395<\/strong>) per shot at launch, but it is now reimbursed at just <strong>RMB 778 per 80 mg shot<\/strong>.&nbsp; National insurance covers only approx. 70-80% of&nbsp;total drug cost, the remainder falls on the patient.&nbsp; This amounts to approx. USD 10k annually paid by insurance, and an extra USD 2-3k out of pocket paid by the patient for a 160 mg\/wk dosing regimen.&nbsp; However, half that dose seems to work well too, bringing costs down for insurers and individuals.&nbsp; Remember, the prevalence of IgAN is much higher in China and SEA than in Western countries.<a href=\"#_ftn11\" id=\"_ftnref11\">[11]<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">That said, you can safely assume premium pricing in the USA where the disease is less prevalent and drug costs uncontrolled.&nbsp; Hence,&nbsp; the WAC of sibeprenlimab\/VOYXACT comes in at approx. <strong>USD 390k<\/strong> annually.<a href=\"#_ftn12\" id=\"_ftnref12\">[12]<\/a>&nbsp; For iptacopan\/FABHALTA, the WAC is in the same range: approx. <strong>USD 550k<\/strong> annually.<a href=\"#_ftn13\" id=\"_ftnref13\">[13]<\/a>&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Questions about the longer-term efficacy and safety of these drugs will be addressable in a few years, after market introduction.&nbsp; It\u2019s anyone\u2019s guess, but biologicals are usually quite safe.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As a next step, we would like to get away from injectables and have more oral options.&nbsp; Iptacopan is an oral drug and has good efficacy\/safety data.&nbsp; What about an oral complement C5a receptor blocker?&nbsp; Something like avacopan, but with qd oral dosing and without liver toxicity, which would be really nice to have.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Companies like chronic diseases that require life-long symptomatic treatments.&nbsp;There is nothing wrong with palliative therapy when RAAS is the only alternative.&nbsp; But we really need more research on the etiologic \/ causative triggers that lead to Gd-IgA1 formation if this is, indeed, the trigger for IgAN.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The research advances in the last 2 decades are impressive; in another 20 years the IgAN chapter will be rewritten completely.&nbsp; We hope for a curative intervention.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>ABBREVIATIONS<\/strong><br \/>ACE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angiotensin-converting enzyme<br \/>APRIL&nbsp;&nbsp;&nbsp;&nbsp; a proliferation-inducing ligand<br \/>ARB&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angiotensin-receptor blocker<br \/>BAFF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; B-cell activating factor<br \/>CKD&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic kidney disease<br \/>eGFR&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; estimated glomerular filtration rate<br \/>IA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; interim analysis<br \/>IgAN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IgA nephropathy<br \/>LD&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loading dose<br \/>MD&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; maintenance dose<br \/>NRDL&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National reimbursement drug list \/ China<br \/>PI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; package insert<br \/>RAAS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renin-angiotensin-aldosterone system (ACE\/ARB)<br \/>SGLT2&nbsp;&nbsp;&nbsp;&nbsp; sodium-glucose transport 2 inhibitor<br \/>TBA&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to be announced<br \/>WAC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wholesale acquisition cost&nbsp;<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>REFERENCES<\/strong><br \/><a href=\"#_ftnref1\" id=\"_ftn1\">[1]<\/a> Lafayette R. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.\u00a0 NEJM 2026;394: 647<br \/><a href=\"#_ftnref2\" id=\"_ftn2\">[2]<\/a> Perkovic V.\u00a0 Sibeprenlimab in IgA Nephropathy \u2014 Interim Analysis of a Phase 3 Trial.\u00a0 NEJM \u00a02026;394: 635<br \/><a href=\"#_ftnref3\" id=\"_ftn3\">[3]<\/a> Barratt J . Atacicept in IgA Nephropathy \u2014 Phase 3 Trial Final Efficacy Analysis.\u00a0 NEJM 2026\u00a0 DOI: 10.1056\/NEJMoa2610103<br \/><a href=\"#_ftnref4\" id=\"_ftn4\">[4]<\/a> Rizk D. Sibeprenlimab in IgA Nephropathy \u2014\u00a0 Final Phase 3 Trial Analysis. NEJM 2026\u00a0 DOI: 10.1056\/NEJMoa2609127<br \/><a href=\"#_ftnref5\" id=\"_ftn5\">[5]<\/a> Barratt J. Ravulizumab in IgA Nephropathy \u2014\u00a0 Interim Analysis of a Phase 3 Trial.\u00a0 NEJM 2026 DOI: 10.1056\/NEJMoa2607544<br \/><a href=\"#_ftnref6\" id=\"_ftn6\">[6]<\/a> Barratt J.\u00a0 Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.\u00a0 NEJM 2026\u00a0 DOI: 10.1056\/NEJMoa2608682<br \/><a href=\"#_ftnref7\" id=\"_ftn7\">[7]<\/a> Barratt, J.\u00a0Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.\u00a0 Clin J Am Soc Nephrol 2024 19:452<br \/><a href=\"#_ftnref8\" id=\"_ftn8\">[8]<\/a> Mo B. Efficacy and\u00a0safety of\u00a0complement inhibitors in\u00a0IgAN: a\u00a0systematic review and\u00a0meta\u2011analysis.\u00a0 International Urology Nephrology (2026) 58:201<br \/><a href=\"#_ftnref9\" id=\"_ftn9\">[9]<\/a> Wu M.\u00a0 Efficacy and safety of belimumab in IgA nephropathy: real-world experience.\u00a0 Nephrol Dial Transplant 2026,<br \/><a href=\"#_ftnref10\" id=\"_ftn10\">[10]<\/a> Faull R.\u00a0 Chapter 61: Immunoglobulin A Nephropathy and Henoch-Sch\u00f6nlein Purpura.\u00a0 In: Schrier, Diseases of the Kidney &amp; Urinary Tract.\u00a0 2007 Philadelphia: Wolters Kluwer Health \/ Lippincott Williams and Wilkins.<br \/><a href=\"#_ftnref11\" id=\"_ftn11\">[11]<\/a> <a href=\"https:\/\/search.brave.com\/ask?q=elaborate&amp;conversation=09bbfae4ea5a2b60a4497f811488e1686c48\">https:\/\/search.brave.com\/ask?q=elaborate&amp;conversation=09bbfae4ea5a2b60a4497f811488e1686c48<\/a> (accessed 10\/26\/2026)<br \/><a href=\"#_ftnref12\" id=\"_ftn12\">[12]<\/a> <a href=\"https:\/\/search.brave.com\/ask?q=price+of+Voyxact+in+US&amp;conversation=09bbb2782f476707876d98ebc94ed9862532\">https:\/\/search.brave.com\/ask?q=price+of+Voyxact+in+US&amp;conversation=09bbb2782f476707876d98ebc94ed9862532<\/a> (accessed 10\/26\/2026)<br \/><a href=\"#_ftnref13\" id=\"_ftn13\">[13]<\/a> <a href=\"https:\/\/search.brave.com\/search?q=price+of+Fabhalta+in+US&amp;conversation=09bb973b37f73109e8133349e5ef34cbb3c2\">https:\/\/search.brave.com\/search?q=price+of+Fabhalta+in+US&amp;conversation=09bb973b37f73109e8133349e5ef34cbb3c2<\/a> (accessed 10\/26\/2026)<br \/><a href=\"#_ftn14\">[14]<\/a>\u00a0 Lv J. Telitacicept for IgA Nephropathy \u2014 Interim Analysis of a Phase 3 Trial. N Engl J Med 2026;394:1916<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Earlier this year, the NEJM published interim data on atacicept and sibeprenlimab in IgAN, both well-designed Phase 3 pivotal registration trials of promising drugs [1],[2]. Sponsors were clearly anxious to show the world how well their drug is working, but why publish interim results?&nbsp; After all, IA data are usually <a class=\"more-link\" href=\"https:\/\/allphasepharma.com\/dir\/2026\/10\/27\/8073\/igan-therapy-its-getting-crowded-out-there\/\">Continue reading <span class=\"screen-reader-text\">  IgAN Therapy \u2013 It\u2019s Getting Crowded Out There<\/span><span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":8081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[227,3,18],"tags":[238,1271,2224,2577,2209,2715,2225,2520,2231,2803,2800,2801,2793,2798,2198,2794,1583,2796,2211,2212,2200,2805,2804,174,2559,2583,2210,2791,2535,2718,2806,2792,2790,2716,2208,2802,2576,2795,2582,2797,2799],"class_list":["post-8073","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-alexion","tag-allphase-pharma-consulting","tag-april","tag-april-baff-inhibitor","tag-atacicept","tag-avacopan","tag-baff","tag-belimumab","tag-benlysta","tag-cemdisiran","tag-complement-c5a-inhibitor","tag-complement-c5a-receptor-inhibitor","tag-complement-inhibitors","tag-drug-pricing-china","tag-fabhalta","tag-factor-b-inhibitor","tag-harald-reinhart","tag-i-can-trial","tag-iga-nephropathy","tag-igan","tag-iptacopan","tag-masp-2-blocker","tag-narsoplimab","tag-novartis","tag-nrdl","tag-otsuka-pharmaceuticals","tag-povetacicept","tag-raas","tag-rainier-trial","tag-ravulizumab","tag-regeneron","tag-sglt2-inhibitor","tag-sibeprenlimab","tag-tavneos","tag-telitacicept","tag-ultromiris","tag-vera-therapeutics-origin-3-trial","tag-vertex-pharmaceuticals","tag-visionary-trial","tag-voyxact","tag-wac"],"jetpack_publicize_connections":[],"jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-26d","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":6362,"url":"https:\/\/allphasepharma.com\/dir\/2026\/03\/31\/6362\/igan-therapeutics-the-race-is-on\/","url_meta":{"origin":8073,"position":0},"title":"IgAN Therapeutics &#8211; The Race is On","author":"Harald","date":"March 31, 2026","format":false,"excerpt":"Is there a new trend in the journal world: \u00a0publication of interim analysis (IA) results? The NEJM recently published two articles back to back, both highlighting 9 month 'interim' data from Phase 3 pivotal trials in IgAN. The primary efficacy endpoint used in either study was UPCR at 9 months,\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/03\/UPCR-vs-GFR.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":4416,"url":"https:\/\/allphasepharma.com\/dir\/2025\/05\/30\/4416\/baff-april-inhibitors-homing-in-on-igan\/","url_meta":{"origin":8073,"position":1},"title":"BAFF \/ APRIL Inhibitors Homing in on IgAN","author":"Harald","date":"May 30, 2025","format":false,"excerpt":"Today we discuss the group of BAFF\/APRIL inhibitors, specifically the three TACI mAb constructs that are currently in development. They were tested in a broad gamut of B-cell indications but failed to show efficacy in many. So far, consistent clinical success has been seen only in IgA nephropathy (IgAN), with\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/HR-BLOG-BAFF-APRIL.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/HR-BLOG-BAFF-APRIL.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/05\/HR-BLOG-BAFF-APRIL.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":5735,"url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/08\/5735\/comparison-of-baff-april-inhibitors-2\/","url_meta":{"origin":8073,"position":2},"title":"COMPARISON OF BAFF \/ APRIL INHIBITORS \u2013 2","author":"Harald","date":"November 8, 2025","format":false,"excerpt":"Shortly after posting our last blog on tacicepts, new data was published in the NEJM on the pivotal Phase 3 trial of atacicept.\u00a0 This publication by Lafayette et al. provides results from an IA of the ongoing ORIGIN-3 trial.[1] \u00a0We updated our table with this new information that centers on\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/atacicept-ORIGIN-3-Interim-e1762657582817.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":5697,"url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/03\/5697\/comparison-of-baff-april-inhibitors\/","url_meta":{"origin":8073,"position":3},"title":"COMPARISON OF BAFF \/ APRIL INHIBITORS","author":"Harald","date":"November 3, 2025","format":false,"excerpt":"First, a reminder where the name \u2018Berger\u2019s disease\u2019 or Morbus Berger comes from.\u00a0It was Jean Berger, a French pathologist and doctor, who initially identified IgA deposits on the glomeruli of nephritic patients.\u00a0 This was not so long ago; his publication (in French) dates from 1968.[1] Now the race is heating\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/Povetacicept-PK-e1762226541807.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/Povetacicept-PK-e1762226541807.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/Povetacicept-PK-e1762226541807.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":5771,"url":"https:\/\/allphasepharma.com\/dir\/2025\/11\/17\/5771\/tacicepts-vying-for-your-attention\/","url_meta":{"origin":8073,"position":4},"title":"TACICEPTS VYING FOR YOUR ATTENTION","author":"Harald","date":"November 17, 2025","format":false,"excerpt":"Two posters on tacicepts caught our eyes. First is the Tumlin publication on povetacicept, an oral presentation in the \"Late-Breaking Research\" session. This is an interim look at Phase 1b study data reporting on 17 IgAN patients treated for 48 weeks with a dose of 80 mg and 30 patients\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/11\/TACICEPTS-VYING-FOR-ATTENTION-scaled.jpg?fit=1200%2C338&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":7435,"url":"https:\/\/allphasepharma.com\/dir\/2026\/06\/30\/7435\/drug-development-in-china-moving-beyond-the-me-too-path\/","url_meta":{"origin":8073,"position":5},"title":"DRUG DEVELOPMENT IN CHINA \u2013 Moving Beyond the Me-Too Path","author":"Harald","date":"June 30, 2026","format":false,"excerpt":"We have to thank Liu and colleagues for a thorough review of pharmaceutical development activities in China and elsewhere during the last decade.[1]\u00a0 The authors reviewed a total of 34,844 Phase 1-3 trials, showing a significant uptick in studies initiated by Chinese companies.\u00a0 Compared to 2015, trial numbers have steadily\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/06\/image.jpeg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]}],"jetpack_likes_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2026\/10\/IGAN-DRUGS-e1793087424970.jpg?fit=640%2C180&ssl=1","_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/8073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=8073"}],"version-history":[{"count":9,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/8073\/revisions"}],"predecessor-version":[{"id":8087,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/8073\/revisions\/8087"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/8081"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=8073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=8073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=8073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}